Advances in cancer biology - metastasis最新文献

{"title":"PD-L1 and PD-1 in immune regulation and their implications in blood cancers","authors":"Parisa Shiri Aghbash ,&nbsp;Faezeh Mehdizadeh ,&nbsp;Ghazal Pourbeiragh ,&nbsp;Yalda Yazdani ,&nbsp;Hossein Bannazadeh Baghi ,&nbsp;Abolfazl Jafari Sales ,&nbsp;Mehrdad Pashazadeh ,&nbsp;Parisa Kangari","doi":"10.1016/j.adcanc.2024.100125","DOIUrl":"10.1016/j.adcanc.2024.100125","url":null,"abstract":"<div><p>Because of emerging opportunities for cancer immunotherapy, the capacity to suppress the immune system in order to cure and eradicate cancer is currently a topic of intense study. When the bone marrow microenvironment is exposed to immune suppression, leukemia cells result in the immune system's inability to eliminate malignant cells. To get a better understanding of the immunological possibilities associated with leukemia, clinical trials have explored immunotherapy techniques such as T cell activators, checkpoint inhibitors, antibody medicinal molecules, and cell treatments. One of the most important immune pathways is the programmed cell death 1 (PD1) protein. PD1 is expressed on the surface of T-cells and controls immune reactions. CD274, B7–H1, or PD-L1 are expressed by cells of the myeloid lineage, including macrophages, dendritic cells, effector CD8⁺ T cells, tumor cells, and tumor-associated suppressor cells. Expression of PD-L1 molecule in cancer has been associated to worse prognosis and resistance to anti-cancer therapies in several malignancies. In this review, we update on the expression of PD-1 molecule in malignant hematological tumor cells and describe these molecules which inhibit the immune response to cancer cells. We provide an overview of the current scientific advancements, the significance of immunotherapy strategies and highlighting the potential for further development in targeting this specific molecule. Additionally, ascertaining if PD-1/PD-L1 can be a reliable prognostic for blood cancer diagnosis.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"11 ","pages":"Article 100125"},"PeriodicalIF":2.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000121/pdfft?md5=00e0c675ef6dc26d06e116a1c581384a&pid=1-s2.0-S2667394024000121-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential of mesenchymal stem cells and its exosomes in colorectal cancer: Paving way from preclinical towards clinical road","authors":"Zunaira Ali Baig ,&nbsp;Farzana Shafqat ,&nbsp;Iffat Mushtaq ,&nbsp;Ummara Aslam ,&nbsp;Asma Faryal ,&nbsp;Ayesha Maryam","doi":"10.1016/j.adcanc.2024.100123","DOIUrl":"https://doi.org/10.1016/j.adcanc.2024.100123","url":null,"abstract":"<div><p>Colorectal cancer is one of the most prevalent cancers worldwide. An increasing number of cases around the globe are raising concerns for life quality and survival. Various factors including genetic drivers have been extensively studied regarding the disease risk, progression, and metastasis. However, the signaling mechanisms haven't been studied extensively yet. Various therapeutic methods have been established in combating the disease, and mesenchymal stem cells have come up as a crucial cell-based therapeutic strategy. Mesenchymal stem cells have been regarded as potential targets in various cancer types due to their immune-modulatory functions. They can be isolated from many body tissues including bone marrow, peripheral blood, umbilical cord, and adipose tissue. Exosomes derived from mesenchymal stem cells have been reported to affect the expression of certain proteins associated with colorectal cancer. The current review highlights the potential of mesenchymal stem cells and their derived exosomes in treating cancer by causing cytotoxicity and apoptosis. Further, T-cell mediated modulation of exosomes helps reduce the cellular proliferation in cancer cells.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"11 ","pages":"Article 100123"},"PeriodicalIF":2.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000108/pdfft?md5=3a3361d8001405a8048789c9b7095c04&pid=1-s2.0-S2667394024000108-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141596396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The varied clonal trajectory of liver and lung metastases of colorectal cancer","authors":"Ofer N. Gofrit ,&nbsp;Ben Gofrit ,&nbsp;S. Nahum Goldberg ,&nbsp;Aron Popovtzer ,&nbsp;Jacob Sosna ,&nbsp;Ayala Hubert","doi":"10.1016/j.adcanc.2024.100122","DOIUrl":"https://doi.org/10.1016/j.adcanc.2024.100122","url":null,"abstract":"<div><h3>Background</h3><p>The liver and lungs are the most common sites of colorectal cancer (CRC) metastases. Their involvement can take five different clinical scenarios: lung metastases only, liver metastases only, lung metastases before liver metastases, liver metastases before lung metastases and simultaneous lung and liver metastases. Using clinical and morphological data we studied the clonal trajectory of these scenarios.</p></div><div><h3>Materials and methods</h3><p>A total of 465 (CRC) patients with 7952 liver and 6406 lung metastases were evaluated. Metastases clinical route was deciphered from metastases number, timing, and linear/parallel ratio (LPR)- a computerized parameter used for deducing clonal trajectories. LPR of +1 suggest pure linear dissemination and −1 pure parallel.</p></div><div><h3>Results</h3><p>Lung-only metastases: high percentage of metachronous disease with a long lead time and a low LPR suggest parallel dissemination. Liver-only metastases: Rare metachronous disease with a short lead time, and a high LPR suggest linear spread. Lung-before-liver metastases: rare solitary metastasis, a median gap of 21 months between the organs, high lung and low liver LPRs suggest linear progression to the lungs and parallel dissemination to the liver. Liver-before-lung metastases: low liver and high lung LPRs and a median gap of 16.5 months between the organs suggest parallel dissemination to the liver and linear spread from the liver to the lungs. Simultaneous liver and lung metastases: rare solitary metastasis and similar and high LPRs suggest simultaneous linear progression to both organs.</p></div><div><h3>Conclusions</h3><p>CRC metastases have different dissemination trajectories in different clinical scenarios. This information can potentially impact on clinical management.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"11 ","pages":"Article 100122"},"PeriodicalIF":2.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000091/pdfft?md5=6643c17257215aca6ddde3347b246b1c&pid=1-s2.0-S2667394024000091-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141596397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling cancer metastasis for more efficient therapeutic approaches","authors":"","doi":"10.1016/j.adcanc.2024.100120","DOIUrl":"10.1016/j.adcanc.2024.100120","url":null,"abstract":"","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"11 ","pages":"Article 100120"},"PeriodicalIF":2.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000078/pdfft?md5=f5378a0c97be77ce52e311880f8f2943&pid=1-s2.0-S2667394024000078-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microarray analysis of differentially expressed miRNA in triple negative breast cancer: A study of western India","authors":"Hemangini Vora ,&nbsp;Nikita Bhatt ,&nbsp;Dharvi Shah ,&nbsp;Prabhudas Patel ,&nbsp;Sonia Parikh ,&nbsp;Priti Trivedi ,&nbsp;Shashank Pandya","doi":"10.1016/j.adcanc.2024.100119","DOIUrl":"10.1016/j.adcanc.2024.100119","url":null,"abstract":"<div><h3>Background</h3><p>Triple-negative breast cancer (TNBC) is a genetically and morphologically heterogeneous group with aggressive biological behaviour and specific response to therapy. It accounts for 15–20% of all breast cancers and has two subtypes: basal like and non-basal like. MicroRNAs, which regulate gene expression, play a role in TNBC, potentially acting as oncogenes or tumor suppressors.</p></div><div><h3>Objective</h3><p>Identification of differentially expressed miRNA of potential clinical relevance in TNBC patients.</p></div><div><h3>Methods</h3><p>In this study, miRNA profiling by microarray was performed in tumor tissues of 86 patients with TNBC and 12 healthy individual. Further, the clinical relevance of differentially expressed miRNA was evaluated.</p></div><div><h3>Results</h3><p>In TNBC, 2410 differentially expressed miRNAs were identified and of them 98% were down-regulated, while only 2% were up-regulated. Up regulation of 55 miRNA was observed which target 16 genes. Top 5 genes identified were CDNK1A, p53, TGFB1, APC and HRAS. Of 7 ranking methods, 5 ranking method identified TGFB1 as most significant hub gene. Up regulated miRNA expression then compared between patients who undergone remission and patients who developed disease relapse and only miR-4532 was found upregulated in patients with disease relapse. Further, up regulation of miR-4532 showed a trend of reduced disease-free and overall survival. The down-regulated miRNAs target 238 genes involved in TNBC pathogenesis and progression. The top five hub genes were CDH1, PTEN, MYC, STAT3, and VEGFA. Of 7 ranking methods, 5 ranking method identified STAT3 as most significant hub gene. This study identified 32 novel miRNAs playing a tumor suppressive role and found down-regulated in TNBC. Among these two novel miRNAs, miR-1273g-3p and miR-4459 were found expressed in all TNBC patients. Patients with down-regulation of these miRNAs showed significantly reduced disease-free and overall survival. The ROC curve analysis indicated that miR-4532 and miR-4459 were successful in distinguishing TNBC patients from healthy controls.</p></div><div><h3>Conclusion</h3><p>Our data identified that up regulation of miR-4532 and down regulation of miR-4459 might have the potential to be used as both diagnostic and prognostic biomarker in TNBC.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"10 ","pages":"Article 100119"},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000066/pdfft?md5=7edc26c17cfadb9b2aaa5bc22b8f50d5&pid=1-s2.0-S2667394024000066-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140275687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"mRNA expression profiling of leptin and adiponectin and its receptors in colorectal carcinoma – Biomarker development","authors":"Priyanka Parmesh ,&nbsp;Dinesh Udupi Shastri ,&nbsp;Mallikarjun Goni ,&nbsp;Anil Bapu Bargale ,&nbsp;Ajay Sathyanarayanrao Khandagale","doi":"10.1016/j.adcanc.2024.100118","DOIUrl":"https://doi.org/10.1016/j.adcanc.2024.100118","url":null,"abstract":"<div><h3>Background</h3><p>Metastatic colorectal carcinoma (CRC) is one of the leading causes of mortality of colorectal CRC. Very few prognostic markers and factors affecting progression are studied between metastatic CRC and early CRC. Adipokines are speculated to be associated with this area of interest. In the current study leptin, leptin receptor (Ob-R), adiponectin, adiponectin R1, and adiponectin R2 expression were measured at gene levels to determine a possible association between adipokines and early/metastatic cancer to ultimately identifying a definitive diagnostic marker.</p></div><div><h3>Materials and methods</h3><p>Tissue samples were obtained from 62 patients with radical specimens of CRC. Genes expression was determined by Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR). The association between the clinicopathological parameters and gene expression levels were analyzed by statistical analysis.</p></div><div><h3>Results</h3><p>Overexpression of leptin mRNA is observed in small tumors (size&lt; 5 cms) <em>(P&lt;0.05).</em>b. Leptin receptor were overexpressed in advanced tumors (1.013 ± 0.152) than early tumors (0.453 ± 0.131). c.Adiponectin expression was higher in early tumors (1.535 ± 0.406) than in advanced tumors (0.48 ± 0.148). d. Distant organ metastasis shows under-expression of adipoR1. e.Overexpression of adipoR2 is seen in small (size&lt;5 cms<em>) (P&lt;0.05</em>) tumors.</p></div><div><h3>Conclusion</h3><p>LEPR is better indicator of advancement of tumor than Leptin. ADIPOR1 is a better indicator in advanced CRC than ADIPOR2 and ADIPOQ.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"10 ","pages":"Article 100118"},"PeriodicalIF":0.0,"publicationDate":"2024-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000054/pdfft?md5=4db6465437748b306c5be46674351fde&pid=1-s2.0-S2667394024000054-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140123279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV and p16 expression association with 5-year survival in oral squamous cell carcinoma patients of north-east India","authors":"Rajjyoti Das ,&nbsp;Rupesh Kumar ,&nbsp;Avdhesh Kumar Rai ,&nbsp;Anupam Sarma ,&nbsp;Lopamudra Kakoti ,&nbsp;Amal Chandra Kataki ,&nbsp;Mouchumee Bhattacharyya ,&nbsp;Manoj Kalita","doi":"10.1016/j.adcanc.2024.100115","DOIUrl":"10.1016/j.adcanc.2024.100115","url":null,"abstract":"<div><h3>Background</h3><p>In our study, we examined the 5-year survival of OSCC patients with HPV positive or negative status along with p16 protein expression.</p></div><div><h3>Method</h3><p>A total of 72 biopsy tissue specimens from histologically confirmed oral squamous cell carcinoma (OSCC) patients were collected. HPV detection and genotyping were performed using HPV E6/E7 and HPV- type-specific multiplex primer for nested-PCR. Immunohistochemistry evaluation of pl6 was conducted. SPSS statistical software (ver 20) was used for data analysis.</p></div><div><h3>Results</h3><p>High risk-HPV (hr-HPV) DNA positivity was found in 27.7% (n = 20) of OSCC patients. Stage III OSCC patients were 7.80 times more likely to survive 5 years than stage IV patients (OR-7.80 CI-95%; P-0.03). Among the hr-HPV positive OSCC patients, we found that the median survival time for the 1st year (95%), 3 years (78.5%), and 5 years (38.5%) was significantly higher than that of the hr-HPV negative [1st year (78.6%), 3 years (45.2%) and 5 years (38.5%)] OSCC patients (P-0.03 The survival of male patients with hr-HPV positive OSCC is 9.75 times greater than the survival of patients with HPV negative OSCC (OR-9.75; CI-95%; P-0.05). The p16 expression level (low to overexpression) group and negative P16 expression group of OSCC patients have not demonstrated a significant association with 5-year survival.</p></div><div><h3>Conclusion</h3><p>We conclude that in OSCC cases of North-East India, the presence of hr-HPV in OSCC cases could be a good predictor of 5-year survival rate. Expression of p16 does not appear to have any significant association with 5-year survival.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"10 ","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000029/pdfft?md5=76e250bd5af3b99faaf0b6b06ebf6f4e&pid=1-s2.0-S2667394024000029-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139885421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic insights on the role of competing endogenous RNA regulatory networks (ceRNETs) in small cell lung cancer","authors":"Sachin Kumar","doi":"10.1016/j.adcanc.2024.100117","DOIUrl":"https://doi.org/10.1016/j.adcanc.2024.100117","url":null,"abstract":"<div><p>Small cell lung cancer (SCLC) is characterized by early metastatic dissemination and rapid emergence of chemoresistance resulting in a very dismal prognosis. SCLC tumors are characterized by nearly universal biallelic inactivation of TP53 and RB1 genes and are classified into four molecular subtypes based on the expression of lineage-specific transcription factors. The integration of information encoded by the coding and non-coding genome has significantly improved our understanding of the contribution of various non-coding RNAs (ncRNAs), such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), in the pathogenesis of SCLC. This has led to the concept of competing endogenous RNAs (ceRNAs) where the presence of the same miRNA response elements in one or more coding and ncRNAs may result in them competing for the same miRNA. Several studies have looked at the role of lncRNAs and circRNAs as ceRNAs by constructing ceRNA regulatory networks (ceRNETs). In this review, we discuss the role of ceRNETs in regulating various cancer hallmarks, including cell proliferation, invasion, migration, EMT, apoptosis, and chemoresistance of SCLC cells. We also discuss the potential of lncRNAs and circRNAs as biomarkers for diagnosis, prognosis, and predicting chemoresistance of SCLC.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"10 ","pages":"Article 100117"},"PeriodicalIF":0.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000042/pdfft?md5=6c287c64ac63043305834fee6a1a9f9a&pid=1-s2.0-S2667394024000042-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139653092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 on the clinical staging of breast cancer: A cross-sectional study","authors":"Thais Zilles Fritsch ,&nbsp;Gabriel Ben Bordinhão ,&nbsp;Laura Martin Manfroi ,&nbsp;Rafaela Vidal Paiva de Sousa ,&nbsp;Maiara Rosa dos Santos ,&nbsp;Giovana Diniz de Oliveira Bonetti ,&nbsp;Rafael José Vargas Alves ,&nbsp;Claudia Giuliano Bica","doi":"10.1016/j.adcanc.2024.100116","DOIUrl":"https://doi.org/10.1016/j.adcanc.2024.100116","url":null,"abstract":"<div><p>Following the declaration of COVID-19 as a pandemic in February 2020, one of the most important public health impacts was the decrease in demand for screening mammography, with a consequent impact on the early diagnosis of breast cancer. Therefore, the aim of this study was to compare the initial clinical staging of women with breast cancer in the pre-pandemic and pandemic periods at a reference cancer hospital in southern Brazil. We performed a retrospective cross-sectional study with a database of surgical procedures on the female breast, comparing the years 2019 and 2020. A total of 1733 surgical procedures for diagnostic and curative purposes were evaluated. Among these patients, 491 (49.2 %) were diagnosed with breast cancer in 2019 and 335 (45.5 %) in 2020. We excluded 907 patients due to benign diagnoses, carcinoma in situ, recurrence, presence of metastases, missing data, and other findings. When comparing 2019 and 2020, we found no significant difference in clinical staging or tumor phenotype. The median time in days between mammography and first treatment was also similar in both years. However, we observed a higher frequency of lobular histologies and neoadjuvant therapy as first treatment choice in the pandemic year. In conclusion, there was no significant difference in clinical staging between women diagnosed with breast cancer before and during the pandemic.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"10 ","pages":"Article 100116"},"PeriodicalIF":0.0,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000030/pdfft?md5=f030741135c91cd7818903be0debc5ed&pid=1-s2.0-S2667394024000030-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139653093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success","authors":"Sumel Ashique ,&nbsp;Mithun Bhowmick ,&nbsp;Radheshyam Pal ,&nbsp;Heya Khatoon ,&nbsp;Prashant Kumar ,&nbsp;Himanshu Sharma ,&nbsp;Ashish Garg ,&nbsp;Shubneesh Kumar ,&nbsp;Ushasi Das","doi":"10.1016/j.adcanc.2024.100114","DOIUrl":"https://doi.org/10.1016/j.adcanc.2024.100114","url":null,"abstract":"<div><p>A significant obstacle to treating cancer is multidrug resistance (MDR), which is the capacity of cancerous cells to develop resistance to both traditional and cutting-edge chemotherapeutic treatments. Following the initial discovery that cellular pumps reliant on ATP were the root of chemotherapy resistance, more research has revealed the involvement of additional mechanisms, including increased drug metabolism, reduced drug entry, and compromised apoptotic pathways. Numerous projects have focused on MDR, and innumerable research has been conducted to better understand MDR and develop methods to mitigate its consequences. Multidrug resistance (MDR) is a key challenge in treating cancer. 90% of cancer-related fatalities are brought on by tumor metastasis and recurrence, which is possible with MDR. Drug resistance in cancerous cells is influenced by diverse internal and extrinsic variables, including genetic and epigenetic changes, drug efflux systems, DNA repair mechanisms, apoptosis, and autophagy. In this review paper, we list the potential hazards associated with cancer therapy in general, primarily multidrug resistance developing a theory for colorectal cancer in particular. We discussed the unique instance of multidrug resistance in colorectal cancer in malignancies generally and 5-fluorouracil, curcumin, and lipids as viable therapy options for the condition. The use of nanotechnology (mainly nanoparticles) has facilitated better <em>in vitro</em> as well as <em>in vivo</em> efficacy during preclinical phases, summarized below, allowing for a more thorough investigation of colorectal cancers and pancreatic carcinomas with their translation to following clinical trials.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"10 ","pages":"Article 100114"},"PeriodicalIF":0.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667394024000017/pdfft?md5=e514d971e2f9aa115a596df3e74f0a55&pid=1-s2.0-S2667394024000017-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139487685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}